ahead of #2018ada, $ announced topline results from the ph3 pioneer4&amp;7 studying oral semaglutide in #t2d. both trials met their primary outcomes: non-inferiority to victoza and superiority to januvia. oral ema also showed stat. significant a1c and weight reduction vs. victoza